Jonathan Schulhof, MD
Glaucoma Specialist · Brooklyn, NYNPI 1972893915
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 36.1% of the total. Reporting peaked in 2023 at $16,732 and has fallen 53.9% since, to $7,711 in 2025. Among glaucoma specialist clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $305.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$26K
- Glaukos Corporation$17K
- Alcon$15K
- NEW World Medical,inc.$6K
- AbbVie$3K
- Johnson & Johnson Surgical Vision, Inc.$3K
- plus $3K from 13 others
What the payments were for
- Consulting fees$22,42031%
- Speaking & faculty fees$41,07756%
- Travel & lodging$9211%
- Food & beverage$8,57112%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 31 | $26,399 |
| Glaukos Corporation | 17 | $17,484 |
| Alcon | 36 | $14,874 |
| NEW World Medical,inc. | 23 | $6,023 |
| AbbVie(2 entities) | 78 | $2,605 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $2,529 |
| Regeneron | 1 | $1,575 |
| Ivantis, Inc | 2 | $557 |
| Biotissue Holdings Inc. | 8 | $410 |
| Bausch & Lomb Americas Inc. | 18 | $236 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $92 |
| Thea Pharma Inc. | 3 | $60 |
| Dompe US, Inc. | 3 | $52 |
| Novartis | 2 | $36 |
| Oyster Point Pharma, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$40,043
- Rocklatan$38,845
- SIMBRINZA$11,319
- Travoprost Intraocular Implant - iDose$5,818
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$4,750
- Ahmed Glaucoma Valve$4,351
- Clearpath$3,976
- Kahook Dual Blade$3,351
- Streamline$2,976
- iStent Trabecular Micro-Bypass System Model iS3$2,625
- Tecnis Symfony IOL$2,132
- iStent inject W$2,123
- EYLEA$1,575
- XEN GLAUCOMA TREATMENT SYSTEM$1,000
- iStent Trabecular Micro-Bypass Stent System$1,000
- iDose$788
- Hydrus Microstent$634
- Prokera$245
- AmnioGraft$245
- Streamline Surgical System$244
How this compares
$73,034 in reported general payments places this provider in the 90th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 761 | $470,448 |
| RocklatanNetarsudil Mesylat/Latanoprost | 229 | $170,472 |
| CombiganBrimonidine Tartrate/Timolol | 215 | $105,863 |
| RhopressaNetarsudil Mesylate | 125 | $84,314 |
| VyzultaLatanoprostene Bunod | 99 | $59,263 |
| Difluprednate | 372 | $54,809 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 125 | $45,624 |
| Alphagan PBrimonidine Tartrate | 100 | $44,498 |
| ProlensaBromfenac Sodium | 85 | $41,430 |
| Prednisolone Acetate | 701 | $38,195 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 114 | $24,214 |
| RestasisCyclosporine | 19 | $23,053 |
| Latanoprost | 1,350 | $16,908 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 656 | $13,780 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $2,605 | $643,8621,095 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $26,399 | $254,785354 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $236 | $72,085116 claims |
| AlconSimbrinza, Azopt | $14,874 | $54,964141 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $92 | $41,43085 claims |
| Thea Pharma Inc.Iyuzeh | $60 | $6,68515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in Brooklyn
- Tak Yee Tania TaiBrooklyn$11K
- Shayma JawadBrooklyn$3K
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Sonya DharNew York$19K
- Jacqueline LenociCommack$13K
- Leah UmfreyAlbany$6K
- Smitha VoletiYonkers$5K
- Yvonne OkakaNew York$5K
- Brian KrawitzBronx$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.